CEPHEMVERBINDUNGEN

European patent · EP1556389 · Deleted

Register entry

Publication number
EP1556389
Application number
EP03758919
Kind
European patent with effect for Switzerland and Liechtenstein
Status
Deleted
Specification
Limited
Filed
Oct 27, 2003
Published
Jul 27, 2005
Granted
Jul 25, 2007
Deleted
Oct 28, 2023
Reason
Maximum term reached
IPC classes
C07D 501/46 (2006.01)
A61K 31/546 (2006.01)
A61P 31/04 (2006.01)
Priority
AU 2002952355 30.10.2002
AU 2003904813 04.09.2003
PCT application
PCT/JP2003/013684 27.10.2003
PCT publication
WO2004/039814 13.05.2004
Filing language
English
Source
Swissreg

Supplementary protection certificates

A certificate extends the patent’s protection for a medicine or a plant protection product authorised in Switzerland.

Ceftolozan

C01556389/01 · Medicine · Extended for paediatric use · Protection from Oct 27, 2023 to Apr 26, 2029

Authorisation 65472 (Swissmedic, Mar 3, 2016) · Authorisation 65472 (Swissmedic, Sep 25, 2014) · Authorisation EU/1/15/1032/001 (EEA, Mar 25, 2014)

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Oct 28, 2023

    Maximum term reached

    Published in Swissreg on 28.10.2023

  2. Nov 1, 2022

    Change

    Published in Swissreg on 01.11.2022

  3. Sep 22, 2021

    Change

    Published in Swissreg on 22.09.2021

  4. Sep 22, 2021

    Change

    Published in Swissreg on 22.09.2021

  5. Jun 8, 2016

    Address changed

    Owner
    Astellas Pharma Inc., 3-11, Nihonbashi-Honcho 2-chome,, Chuo-ku, Tokyo 103-8411, Japan, WAKUNAGA PHARMACEUTICAL CO., LTD., 5-36, Miyahara 4-chome,, Yodogawa-ku, Osaka-shi,, Osaka 532-0003, Japan → WAKUNAGA PHARMACEUTICAL CO., LTD., 5-36, Miyahara 4-chome,, Yodogawa-ku, Osaka-shi,, Osaka 532-0003, Japan, Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8411, Japan

    Published in Swissreg on 08.06.2016

  6. Apr 1, 2015

    Change

    Published in Swissreg on 01.04.2015

  7. Feb 17, 2015

    Corrected

    Published in Swissreg on 17.02.2015

  8. Feb 11, 2015

    Change

    Published in Swissreg on 11.02.2015

4 earlier entries
  1. Jul 15, 2014

    Address changed

    Representative
    BOHEST AG, Postfach 160, 4003 Basel → BOHEST AG, Holbeinstrasse 36-38, 4051 Basel

    Published in Swissreg on 15.07.2014

  2. Jun 30, 2008

    Address changed

    Representative
    A. Braun, Braun, Héritier,, Eschmann AG, Patentanwälte, Holbeinstrasse 36-38, 4051 Basel → BOHEST AG, Postfach 160, 4003 Basel

    Published in +pat+ No 12 in 2008

  3. Nov 15, 2007

    Agent entered

    Representative
    A. Braun, Braun, Héritier,, Eschmann AG, Patentanwälte, Holbeinstrasse 36-38, 4051 Basel

    Published in +pat+ No 21 in 2007

  4. Aug 15, 2007

    Granted

    Published in +pat+ No 15 in 2007

Parties

Holder

WAKUNAGA PHARMACEUTICAL CO., LTD.

5-36, Miyahara 4-chome, Yodogawa-ku, Osaka-shi, Osaka 532-0003, JP

Astellas Pharma Inc.

5-1, Nihonbashi-Honcho 2-chome Chuo-ku, Tokyo 103-8411, JP

Agent

BOHEST AG

Holbeinstrasse 36-38, 4051 Basel

Inventor

OHKI, Hidenori, c/o Astellas Pharma Inc.

Chuo-ku, Tokyo 103-8411, JP

OKUDA, Shinya, c/o Astellas Pharma Inc.

Chuo-ku, Tokyo 103-8411, JP

YAMANAKA, Toshio, c/o Astellas Pharma Inc.

Chuo-ku, Tokyo 103-8411, JP

OHGAKI, Masaru, c/o Astellas Pharma Inc.

Chuo-ku, Tokyo 103-8411, JP

TODA, Ayako, c/o Astellas Pharma Inc.

Chuo-ku, Tokyo 103-8411, JP

KAWABATA, Kohji, c/o Astellas Pharma Inc.

Chuo-ku, Tokyo 103-8411, JP

INOUE, Satoshi, Wakunaga Pharmaceutical Co., Ltd.

Takata-gun, Hiroshima 739-1195, JP

MISUMI, Keiji, Wakunaga Pharmaceutical Co., Ltd.

Takata-gun, Hiroshima 739-1195, JP

ITOH, Kenji, Wakunaga Pharmaceutical Co., Ltd.

Takata-gun, Hiroshima 739-1195, JP

SATOH, Kenji, Wakunaga Pharmaceutical Co., Ltd.

Takata-gun, Hiroshima 739-1195, JP

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.